These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2591466)

  • 1. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.
    Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
    Eur J Clin Pharmacol; 1989; 37(1):69-74. PubMed ID: 2591466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant.
    Hooper WD; Dickinson RG; Dunstan PR; Pendlebury SC; Eadie MJ
    Clin Exp Neurol; 1987; 24():105-12. PubMed ID: 3268334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.
    Rouan MC; Lecaillon JB; Godbillon J; Menard F; Darragon T; Meyer P; Kourilsky O; Hillion D; Aldigier JC; Jungers P
    Eur J Clin Pharmacol; 1994; 47(2):161-7. PubMed ID: 7859804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
    Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of oxcarbazepine.
    May TW; Korn-Merker E; Rambeck B
    Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
    Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
    Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother.
    Bülau P; Paar WD; von Unruh GE
    Eur J Clin Pharmacol; 1988; 34(3):311-3. PubMed ID: 3396622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state.
    Cardot JM; Degen P; Flesch G; Menge P; Dieterle W
    Biopharm Drug Dispos; 1995 Oct; 16(7):603-14. PubMed ID: 8785383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
    Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
    Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
    Volosov A; Xiaodong S; Perucca E; Yagen B; Sintov A; Bialer M
    Clin Pharmacol Ther; 1999 Dec; 66(6):547-53. PubMed ID: 10613609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oxcarbazepine in the dog.
    Schicht S; Wigger D; Frey HH
    J Vet Pharmacol Ther; 1996 Feb; 19(1):27-31. PubMed ID: 8992022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
    Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
    J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
    McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
    Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
    Almeida L; Soares-da-Silva P
    J Clin Pharmacol; 2004 Aug; 44(8):906-18. PubMed ID: 15286095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
    Degen PH; Flesch G; Cardot JM; Czendlik C; Dieterle W
    Biopharm Drug Dispos; 1994 Aug; 15(6):519-26. PubMed ID: 7993989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug interactions in children taking oxcarbazepine.
    Sallas WM; Milosavljev S; D'souza J; Hossain M
    Clin Pharmacol Ther; 2003 Aug; 74(2):138-49. PubMed ID: 12891224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.
    Theis JG; Sidhu J; Palmer J; Job S; Bullman J; Ascher J
    Neuropsychopharmacology; 2005 Dec; 30(12):2269-74. PubMed ID: 16052246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
    Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
    Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyponatraemia during oxcarbazepine therapy.
    Pendlebury SC; Moses DK; Eadie MJ
    Hum Toxicol; 1989 Sep; 8(5):337-44. PubMed ID: 2680897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine.
    van Heiningen PN; Eve MD; Oosterhuis B; Jonkman JH; de Bruin H; Hulsman JA; Richens A; Jensen PK
    Clin Pharmacol Ther; 1991 Oct; 50(4):410-9. PubMed ID: 1914377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.